We are experts in plasminogen research
Omnio AB is a biopharmaceutical company specialized in development of new drug products based on the protein plasminogen that regulates inflammation and have immune enhancing effects.
Omino is led by a team of life science entrepreneurs with extensive experience in immunology, partnerships and drug discovery collaborations.
Omnio is developing recombinant plasminogen for treatment of chronic wounds.
The management of chronic wounds is an enormous clinical and economic burden on the health care system.